Therapeutic response of Plasmodium vivax to chloroquine in Bolivia

Arletta Añez, Dennis Navarro-Costa, Omar Yucra, Cecilia Garnica, Viviana Melgar, Manuel Moscoso, Ricardo Arteaga, Gladys Nakao, .

Keywords: Plasmodium vivax, malaria, chloroquine, antimalarials, Bolivia.

Abstract

Introduction. Knowledge of the therapeutic efficacy of chloroquine for Plasmodium vivax infections improves the capacity for surveillance of anti-malarial drug resistance.

Objective. The therapeutic efficacy of chloroquine as treatment was evaluated for uncomplicated Plasmodium vivax malaria in Bolivia.

Materials and methods. An in vivo efficacy study of chloroquine was undertaken in three regions of Bolivia--Riberalta, Guayaramerín and Yacuiba. Two hundred and twenty-three patients (84, 80, and59 in the three regions, respectively) aged over 5 years old were administered with chloroquine (25mg/kg/three days) and followed for 28 days. Blood levels of chloroquine and desethylchloroquine were measured on day 2 and on the day of reappearance of parasitemia. The cumulative incidence of treatment failure was calculated using the Kaplan and Meier survival analysis.

Results. The mean parasitemias (asexual) on day 0 were 6,147 parasites/μl of blood in the Riberalta population, 4,251 in Guayaramerín and 5,214 in Yacuiba. The average blood concentrations of chloroquine-desethylchloroquine during day 2 were 783, 817, and 815 ng/ml, respectively. No treatment failures were observed in Yacuiba, whereas in Riberalta and Guayaramerín, the frequencies of treatment failures were 6.2% and 10%. Blood levels of chloroquine and desethylchloroquine in patients with treatment failure showed values below 70 ng/ml on the day of reappearance of parasitemia.

Conclusion. Resistance of Plasmodium vivax to chloroquine was not demonstrated in three regions of Bolivia.

 

doi: http://dx.doi.org/10.7705/biomedica.v32i4.750

Downloads

Download data is not yet available.
  • Arletta Añez Organización Panamericana de la Salud, Organización Mundial de la Salud, La Paz, Bolivia
  • Dennis Navarro-Costa Organización Panamericana de la Salud, Organización Mundial de la Salud, La Paz, Bolivia
  • Omar Yucra Centro de Salud El Palmar, Yacuiba-Tarija, Bolivia
  • Cecilia Garnica Instituto Nacional de Laboratorios en Salud, Centro Nacional de Análisis de Medicamentos y Tóxicos CONCAMYT, La Paz, Bolivia
  • Viviana Melgar Instituto Nacional de Laboratorios en Salud, Centro Nacional de Análisis de Medicamentos y Tóxicos CONCAMYT, La Paz, Bolivia
  • Manuel Moscoso Instituto Nacional de Laboratorios en Salud, Centro Nacional de Análisis de Medicamentos y Tóxicos CONCAMYT, La Paz, Bolivia
  • Ricardo Arteaga Hospital San Gabriel, Guayaramerín-Beni, Bolivia
  • Gladys Nakao Laboratorio Programa de Malaria, Riberalta-Beni, Bolivia

References

World Health Organization. World Malaria Report 2009. Washington: WHO; 2009. Fecha de consulta: 15 octubre de 2010. Disponible en: http://www.who.int/malaria/world_malaria_report_2009/en/index.html.

Organización Panamericana de la Salud, Organización Mundial de la Salud.142a Sesión del Comité Ejecutivo Malaria: Informe sobre la situación actual CE142/16. Washington, D.C.: OPS/OMS; 2008.

Heggenhougen KH, Hackenthal V, Vivek P. The behavioural and social aspects of malaria and its control: An introduction and annotated bibliography. UNDP, World Bank, WHO – Special Programme for Research and Training in Tropical Diseases. Geneva: WHO; 2003.

Uhlemann AC, Yuthavong Y, Fidock D. Mechanism of antimalarial drug action and resistance. En: Sherman IW, editor. Molecular approaches to malaria. Washington DC: ASM Press; 2005. p-229-61.

Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet. 1989; 2:1183-4. http://dx.doi.org/10.1128/ AAC.48.11.4075-4083.2004

Baird JK, Sustriayu Nalim MF, Basri H, Masbar S, Leksana B, Tjitra E, et al. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg. 1996;90:409-11. http://dx.doi.org/10.1016/S0035-9203(96)90526-X,

Baird JK, Basry H, Subianto B, Fryaudff DJ, Mc Elroy PD, Leksana B, et al. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis. 1995;171:1678-82. http://dx.doi.org/10.1093/infdis/171.6.1678

Baird JK, Leksana B, Masbar S, Sutanihardja MA, Fryauff DJ, Subianto B. Whole blood chloroquine concentrations with Plasmodium vivax infection in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1997;56:618-20.

Tulu AN, Webbeg RH, Schellenberg JA, Bradley DJ. Failure of chloroquine treatment for malaria in the highlands of Ethiopia. Trans R Soc Trop Med Hyg. 1996;90:556-7.

Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, et al. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J. 2008;7:220. http://dx.doi.org/10.1186/1475-2875-7-220

Phillips EJ, Keystone JS, Kain KC. Failure of combined chloroquine and high dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis. 1996;23:1171-3. http://dx.doi.org/10.1093/clinids/23.5.1171

Alecrim MC, Alecrim W, Macedo V. Plasmodium vivax resistance to chloroquine (R2) and mefloquine (R3) in Brazilian Amazon Region. Rev Soc Bras Med Trop. 1999;32:67-8. http://dx.doi.org/10.1590/S0037-868219990-00100013

Soto J, Toledo J, Gutiérrez P, Luzz M, Llinás N, Cedeno N, et al. Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg. 2001;65:90-3.

Baird KJ. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009;3:508-34. http://dx.doi.org/10.1128/ CMR.00008-09

Ruebush TK, Zegarra J, Cairo J, Andersen EM, Green M, Pillai DR, et al. Chloroquine-resistant Plasmodium vivax malaria in Peru. Am J Trop Med Hyg. 2003;69:548-52.

De Santana Filho FS, Lima-Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE, Vieira JL, et al. Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis. 2007;13:1125-9. http://dx.doi.org/10.3201/eid1307.061386

Castillo CM, Osorio LE, Palma GI. Assessment of therapeutic response of Plasmodium vivax and Plasmodium falciparum to chloroquine in a Malaria transmission free area in Colombia. Mem Inst Oswaldo Cruz. 2002;97:559-62. http://dx.doi.org/10.1590/S0074-02762002000400020

Martínez E, Yucra WO, Castro V, Figueroa RV, De la Cruz L, Téllez C, et al. Evaluación de la eficacia de la cloroquina para el tratamiento de la malaria por Plasmodium vivax en Yacuiba, Tarija, Bolivia. Cuad Hosp Clin. 2009;54:27-33.

Ministerio de Salud y Deportes Bolivia. Dirección General de Servicios de Salud. Unidad de Epidemiología. Tratamiento de la malaria actual. La Paz: Ministerio de Salud y Deportes Bolivia; 2007. p. 1-4.

World Health Organization. Reviewing and changing the antimalarial treatment policy. En: Malaria case management: Operations manual. Ginebra: WHO; 2009. p. 66. Fecha de consulta: 30 de noviembre de 2010. Disponible en: http://www.who.int/malaria/publications/atoz/malaria_case_management_operations_manual.pdf.

Ministerio de Salud y Deportes, Programa Nacional de Malaria. Situación Actual de la malaria en Bolivia. Parte Epidemiológico. La Paz: Ministerio de Salud y Deportes; 2009.

Garron A, Mollinedo R. La malaria en Bolivia. Revista Médica La Paz. 2000;7:57-61.

Organización Panamericana de la Salud, Organización Mundial de la Salud. Protocolo genérico para estudios in vivo de eficacia de los medicamentos antimaláricos en las Américas. Washington: OPS/OMS, 2003. Fecha de consulta: 5 de diciembre de 2009. Disponible en: http://www.paho.org/spanish/AD/DPC/CD/mal-antimalarials.htm.

Organización Panamericana de la Salud, Organización Mundial de la Salud. Guía práctica para estudios in vivo de eficacia de los medicamentos antimaláricos en las Américas. Washington: OPS/OMS; 2003. Serie OPS/DPC/CD/240/03. Fecha de consulta: 18 de junio de 2009. Disponible en: http://www.paho.org/spanish/AD/DPC/CD/guia-practica.htm.

Ruebush TK, Marquiño W, Zegarra J, Neyra D, Villaroel R, Ávila JC, et al. Practical aspects of in vivo antimalarial drug efficacy testing in the Americas. Am J Trop Med Hyg. 2003;68:391-7.

Jiménez M. Guía práctica del diagnóstico de la malaria. Publicación 154, Serie Documentos Técnicos y Normativos. La Paz: Ministerio de Salud y Deportes; 2010.

Bell DJ, Nyirongo SK, Molyneux ME, Winstanley PA, Ward SA. Practical HPLC methods for the quantitative determination of common antimalarials in Africa. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;847:231-6. http://dx.doi.org/10.1016/j.jchromb.2006.10.020

Baird JK. Effectiveness of antimalarial drugs. N Engl J Med. 2005;352:1565-77. http://dx.doi.org/10.1056/NEJMra043207

World Health Organization. Plasmodium vivax. Methods for surveillance of antimalarial drugs efficacy. Geneva:WHO; 2004. p. 14.

Baird JK, Leksana B, Masbar S, Fryauff D, Sutanihardja A, Suradi F, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: Timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg. 1997;56:621-6.

Baird JK. Chloroquine resistence in Plasmodium vivax. Antimicrob Agents Chemother. 2004;48:4075-83. . http://dx.doi.org/10.1128/ AAC.48.11.4075-4083.2004

Murphy GS, Basri H, Purnomo MS, Andersen EM, Bangs MJ, Mount DL, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet. 1993;341:96-100. http://dx.doi.org/10.1016/0140-6736(93)92568-E

Organización Mundial de la Salud. Instrumento y ejercicio para estudios in vivo de eficacia de los medicamentos antimaláricos en las Américas. Ginebra: OMS; 2004. Fecha de consulta: 16 de agosto de 2009. Disponible en: http://www.paho.org/english/ad/dpc/cd/mal-instrument-28daylow-2.xls.

Baird JK. Neglect of Plasmodium vivax malaria. Trends Parasitol. 2007;23:533-9. http://dx.doi.org/10.1016/j.pt.2007.08.011

World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: WHO; 2009. p. 9.

Ketema T, Bacha K, Birhanu T, Petros B. Chloroquineresistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malar J. 2009;30;8:177. . http://dx.doi.org/10.1186/1475-2875-8-177

Sutanto I, Suprijanto S, Nurhayati, Manoempil P, Baird JK. Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. Am J Trop Med Hyg. 2009;81:338-42.

Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet. 2001;40:343-73.

Guzmán V, Carmona-Fonseca J. El citocromo P-450 y la respuesta terapéutica a los antimaláricos. Rev Panam Salud Pública. 2006;19:9-22. http://dx.doi.org/10.1590/S1020-49892006000100003

Blair S, Carmona J, Correa A. Malaria en niños: relación entre nutrición e inmunidad. Rev Panam Salud Pública. 2002;11:5-14. http://dx.doi.org/10.1590/S1020-49892002000100002

Guengerich FP. Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am J Clin Nutr. 1995;61(Suppl.3):651S-8S.

Villalobos-Salcedo JM, Tada MS, Kimura E, Menezes J, Pereira-da-Silva LH. In-vivo sensitivity of Plasmodium vivax isolates from Rondonia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. Ann Trop Med Parasitol. 2000;94:749-58.

Blair ST, Tobón AC, Echeverri MR, Álvarez GS, Carmona JF. Adecuada respuesta clínica y parasitológica de Plasmodium vivax a la cloroquina en Colombia (Turbo, Antioquia), 2001. Infectio. 2002;6:21-6.

How to Cite
1.
Añez A, Navarro-Costa D, Yucra O, Garnica C, Melgar V, Moscoso M, et al. Therapeutic response of Plasmodium vivax to chloroquine in Bolivia. biomedica [Internet]. 2012 Dec. 1 [cited 2024 May 12];32(4):527-35. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/750

Some similar items:

Published
2012-12-01
Section
Original articles

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code